Dr. Lal Path Labs Share Price Today

Dr Lal PathLabs subsidiary acquires remaining 30% stake in CentraPath

PathLabs Unifiers acquires remaining 30% stake in CentraPath Labs. Acquisition completed on October 13, 2026, for cash consideration. Price paid is ₹1,608.352 per share for the equity stake. CentraPath Labs becomes wholly owned subsidiary of PathLabs Unifiers.

Dr Lal PathLabs receives intimation of IT dept appeal before ITAT for AY 2022-23

Dr. Lal PathLabs received intimation on October 7, 2026 of an Income Tax Department appeal filed before the Income Tax Appellate Tribunal, New Delhi. The appeal challenges an appellate order for AY 2022-23 under section 250 of the Income Tax Act, 1961. The dispute relates to disallowances of ESOP expenses of INR 32,66,18,927/- that the Commissioner of Income Tax (Appeals) had allowed as relief to the company. The company does not reasonably expect the outcome of the appeal to have any material impact on its operations or finances.

Dr Lal PathLabs completes SN Genelab stake acquisition

Dr Lal PathLabs completed the acquisition of a stake in SN Genelab Private Limited on October 1, 2026. The deal follows board approval communicated to exchanges on September 24, 2026. Disclosures were made under Regulation 30 of SEBI Listing Regulations and related circulars.

Dr Lal PathLabs completes 80% stake acquisition in Ghana firm

Dr Lal PathLabs subsidiary acquires 80% stake in Sunshine Healthcare Limited. SHL becomes a step-down subsidiary of the Indian diagnostic chain. Transaction completed on September 26, 2026, following July board approval.

Dr Lal Pathlabs acquires 70% stake in SN Genelab for up to ₹168 crore

Acquired 70% stake in SN Genelab for up to ₹168 crore plus ₹31.5 crore earn-out. Transaction aims to expand genomics diagnostic capabilities. Completion expected by November 30, 2026. Target reported FY26 turnover of ₹57.96 crore, up from ₹43.27 crore in FY24.

Dr Lal Pathlabs completes 30% stake subscription in Neuome Technologies

Dr Lal Pathlabs completed subscription of 30% stake in Neuome Technologies. Transaction finalized on August 27, 2026 via wholly owned subsidiary. Neuome becomes an associate company of the parent firm. Disclosure made under Regulation 30 of SEBI Listing Regulations.